Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 748

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 748
---
 Approval).

(e) . The
Company shall have furnished all required materials to the Transfer Agent to reflect the issuance of the Shares at the Closing.

D-23

(f) . Since the date hereof, no event or series of events shall have
occurred that has had or would reasonably be expected to have a Material Adverse Effect.

(g) . The
Company shall have delivered to the Purchasers and the Placement Agent the opinion of Wilson Sonsini Goodrich & Rosati, P.C., dated as of the Closing Date in customary form and substance to be reasonably agreed upon with the Purchasers.

(h) . The Chief Executive Officer of the Company shall have delivered to the Purchasers at the Closing Date
a certificate in form and substance reasonably satisfactory to the Purchasers certifying that the conditions specified in , , and of this Agreement have been fulfilled.

(i) . The Secretary of the
Company shall have delivered to the Purchasers at the Closing Date a certificate certifying (i) the Amended and Restated Certificate of Incorporation; (ii) the Amended and Restated Bylaws; and (iii) resolutions of the Company’s
Board of Directors (or an authorized committee thereof) approving this Agreement and the transactions contemplated by this Agreement.

(j) . The Company shall have executed and delivered the Registration Rights Agreement in the form
attached hereto as (the “Registration Rights Agreement”) to the Purchasers.

(k) . The Common Stock shall be listed on a National Exchange and shall not have been suspended, as of the Closing Date, by the SEC or the National Exchange from trading thereon nor shall suspension by the SEC or the National Exchange
have been threatened, as of the Closing Date, either (i) in writing by the SEC or the National Exchange or (ii) by falling below the minimum listing maintenance requirements of the National Exchange (with a reasonable prospect of delisting
occurring after giving effect to all applicable notice, appeal, compliance and hearing periods); and the Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Shares and Warrant Shares and
shall have received confirmation from Nasdaq that it has completed its review of such form with no objections to the transactions contemplated herein.

(l) . The Company shall have obtained the Required Stockholder Approval.

(m) . The License Agreement shall be in full force and effect.

6.2 . The obligation of the Company to consummate the
transactions to be consummated at the Closing, and to issue and sell